Natixis Advisors, L.P. Amgen Inc Transaction History

Natixis Advisors, L.P.

$46 Billion
Q2 2024

A detailed history of Natixis Advisors, L.P. transactions in Amgen Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 277,632 shares of AMGN stock, worth $87.7 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

277,632

Previous 247,150 12.33%

Holding current value

$87.7 Million

Previous $70.3 Million 23.45%

% of portfolio

0.19%

Previous 0.16%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$262.75 - $319.31 $8.01 Million - $9.73 Million	30,482 Added 12.33%	277,632 $86.7 Million
Q1 2024 Apr 25, 2024	SELL	$268.87 - $324.56 $719,764 - $868,847	-2,677 Reduced 1.07%	247,150 $70.3 Million
Q4 2023 Feb 06, 2024	BUY	$255.7 - $288.46 $4.36 Million - $4.92 Million	17,043 Added 7.32%	249,827 $72 Million
Q3 2023 Nov 13, 2023	BUY	$218.65 - $271.46 $7.17 Million - $8.9 Million	32,776 Added 16.39%	232,784 $62.6 Million
Q2 2023 Aug 15, 2023	SELL	$214.27 - $253.37 $1.15 Million - $1.36 Million	-5,358 Reduced 2.61%	200,008 $44.4 Million
Q1 2023 May 11, 2023	BUY	$225.79 - $275.2 $1.49 Million - $1.81 Million	6,585 Added 3.31%	205,366 $49.6 Million
Q4 2022 Jan 27, 2023	BUY	$229.03 - $291.01 $1.83 Million - $2.33 Million	7,991 Added 4.19%	198,781 $52.2 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $1.02 Million - $1.15 Million	-4,554 Reduced 2.33%	190,790 $43 Million
Q2 2022 Aug 12, 2022	BUY	$230.71 - $256.74 $6.33 Million - $7.05 Million	27,447 Added 16.35%	195,344 $47.5 Million
Q1 2022 May 12, 2022	BUY	$219.27 - $242.57 $4.05 Million - $4.48 Million	18,481 Added 12.37%	167,897 $40.6 Million
Q4 2021 Feb 08, 2022	BUY	$198.88 - $227.6 $2.22 Million - $2.54 Million	11,178 Added 8.09%	149,416 $33.6 Million
Q3 2021 Nov 15, 2021	SELL	$212.27 - $248.7 $3.58 Million - $4.19 Million	-16,866 Reduced 10.87%	138,238 $29.4 Million
Q2 2021 Aug 12, 2021	BUY	$233.58 - $259.14 $434,225 - $481,741	1,859 Added 1.21%	155,104 $37.8 Million
Q1 2021 May 05, 2021	BUY	$221.91 - $258.6 $2.12 Million - $2.47 Million	9,536 Added 6.64%	153,245 $38.1 Million
Q4 2020 Feb 12, 2021	SELL	$216.38 - $257.67 $6.09 Million - $7.25 Million	-28,126 Reduced 16.37%	143,709 $33 Million
Q3 2020 Nov 12, 2020	SELL	$234.65 - $260.95 $3.07 Million - $3.41 Million	-13,064 Reduced 7.07%	171,835 $43.7 Million
Q2 2020 Aug 11, 2020	SELL	$197.81 - $242.74 $30.7 Million - $37.6 Million	-154,954 Reduced 45.59%	184,899 $43.6 Million
Q1 2020 Apr 27, 2020	BUY	$182.24 - $241.7 $1.64 Million - $2.18 Million	8,999 Added 2.72%	339,853 $68.9 Million
Q4 2019 Feb 10, 2020	BUY	$189.21 - $243.2 $3.01 Million - $3.87 Million	15,901 Added 5.05%	330,854 $79.8 Million
Q3 2019 Nov 12, 2019	BUY	$174.11 - $208.62 $1.94 Million - $2.33 Million	11,156 Added 3.67%	314,953 $60.9 Million
Q2 2019 Aug 12, 2019	BUY	$166.7 - $195.41 $94,852 - $111,188	569 Added 0.19%	303,797 $56 Million
Q1 2019 May 15, 2019	BUY	$180.87 - $203.88 $1.39 Million - $1.57 Million	7,705 Added 2.61%	303,228 $57.6 Million
Q4 2018 Feb 13, 2019	SELL	$178.4 - $208.25 $70,824 - $82,675	-397 Reduced 0.13%	295,523 $57.5 Million
Q3 2018 Nov 13, 2018	SELL	$185.29 - $208.89 $206,598 - $232,912	-1,115 Reduced 0.38%	295,920 $61.3 Million
Q2 2018 Aug 14, 2018	SELL	$166.05 - $186.51 $1.66 Million - $1.86 Million	-9,977 Reduced 3.25%	297,035 $0
Q1 2018 May 10, 2018	BUY	$169.43 - $198.0 $2.57 Million - $3 Million	15,153 Added 5.19%	307,012 $52.3 Million
Q4 2017 Feb 14, 2018	BUY	$168.79 - $188.59 $865,555 - $967,089	5,128 Added 1.79%	291,859 $50.8 Million
Q3 2017 Nov 14, 2017	BUY	$167.29 - $191.0 $48 Million - $54.8 Million	286,731	286,731 $53.5 Million

Others Institutions Holding AMGN

# of Institutions

3,073

Shares Held

417M

Call Options Held

7.19M

Put Options Held

6.28M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $169B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Amgen Inc Transaction History